Molecular medicine (Cambridge, Mass.) · 2026
Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Fengqin, Wang Yanzhe, Liu Xia, Wu Yue, Miao Naijun, Wang Jialing, Chen Xinyue, Wu Tong, Fu Qiao, Zeng Chuchu, Zhang Nan, Xie Xinmiao, Wang Xiaoxia
Аннотация
BACKGROUND: Hyperuricemic nephropathy (HN) is a prevalent metabolic disorder characterized by tubulointerstitial inflammation and fibrosis, driven primarily by aberrant NLR family pyrin domain containing 3 (NLRP3) inflammasome activation. However, effective therapies targeting this pathogenic axis remain elusive. We aimed to identify a pharmacological intervention for HN and elucidate its mechanisms.
METHODS: A targeted phenotypic screen of natural phenolic compounds was conducted against uric acid (UA)-induced inflammasome responses. Multi-omics profiling, molecular docking, and multi-dimensional biophysical assays-including surface plasmon resonance, cellular thermal shift assays, and circular dichroism-and site-directed mutagenesis were utilized to identify and characterize the direct molecular target. The underlying post-translational regulatory mechanism was investigated through co-immunoprecipitation and ubiquitination assays. In vivo efficacy and short-term tolerability were evaluated in a rat model of HN. Clinical relevance was assessed via renal biopsies and clinical sample analysis.
RESULTS: We identified p-coumaric acid (p-CA) as a potent pharmacological candidate. Mechanistically, p-CA engages the Cathepsin B (CTSB) active-site/occluding-loop region, involving residues Cys26 and His110, and suppresses CTSB enzymatic activity. Notably, we uncovered a post-lysosomal regulatory model in which UA-induced lysosomal CTSB leakage is associated with a CTSB activity-associated reduction in WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) protein abundance/stability, thereby impairing WWP1-dependent K48-linked polyubiquitination and proteasomal clearance of NLRP3 and promoting inflammasome activation. p-CA-mediated CTSB inhibition preserves WWP1 protein abundance, restores NLRP3 proteasomal clearance, and attenuates downstream pyroptosis, inflammation, and fibrogenesis. CTSB knockdown attenuated the additional protective effect of p-CA, while pharmacological CTSB inhibition phenocopied p-CA, supporting CTSB pathway dependence. Furthermore, in vivo evaluations demonstrated that p-CA exerts urate-independent renoprotection without overt short-term systemic toxicities associated with synthetic CTSB inhibitors. Clinically, aberrant CTSB and NLRP3 upregulation correlated with impaired renal function in patients from the hyperuricemia-associated CKD cohort.
CONCLUSIONS: Our findings support the CTSB-WWP1-NLRP3 regulatory axis as a previously unrecognized pathogenic mechanism of HN, revealing how lysosomal damage drives inflammasome hyperactivation by disrupting ubiquitin-dependent clearance. The precise molecular mechanism linking CTSB activity to WWP1 turnover remains to be fully defined. Targeting CTSB with p-CA provides a promising prophylactic or co-treatment candidate for HN warranting further translational evaluation.
METHODS: A targeted phenotypic screen of natural phenolic compounds was conducted against uric acid (UA)-induced inflammasome responses. Multi-omics profiling, molecular docking, and multi-dimensional biophysical assays-including surface plasmon resonance, cellular thermal shift assays, and circular dichroism-and site-directed mutagenesis were utilized to identify and characterize the direct molecular target. The underlying post-translational regulatory mechanism was investigated through co-immunoprecipitation and ubiquitination assays. In vivo efficacy and short-term tolerability were evaluated in a rat model of HN. Clinical relevance was assessed via renal biopsies and clinical sample analysis.
RESULTS: We identified p-coumaric acid (p-CA) as a potent pharmacological candidate. Mechanistically, p-CA engages the Cathepsin B (CTSB) active-site/occluding-loop region, involving residues Cys26 and His110, and suppresses CTSB enzymatic activity. Notably, we uncovered a post-lysosomal regulatory model in which UA-induced lysosomal CTSB leakage is associated with a CTSB activity-associated reduction in WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) protein abundance/stability, thereby impairing WWP1-dependent K48-linked polyubiquitination and proteasomal clearance of NLRP3 and promoting inflammasome activation. p-CA-mediated CTSB inhibition preserves WWP1 protein abundance, restores NLRP3 proteasomal clearance, and attenuates downstream pyroptosis, inflammation, and fibrogenesis. CTSB knockdown attenuated the additional protective effect of p-CA, while pharmacological CTSB inhibition phenocopied p-CA, supporting CTSB pathway dependence. Furthermore, in vivo evaluations demonstrated that p-CA exerts urate-independent renoprotection without overt short-term systemic toxicities associated with synthetic CTSB inhibitors. Clinically, aberrant CTSB and NLRP3 upregulation correlated with impaired renal function in patients from the hyperuricemia-associated CKD cohort.
CONCLUSIONS: Our findings support the CTSB-WWP1-NLRP3 regulatory axis as a previously unrecognized pathogenic mechanism of HN, revealing how lysosomal damage drives inflammasome hyperactivation by disrupting ubiquitin-dependent clearance. The precise molecular mechanism linking CTSB activity to WWP1 turnover remains to be fully defined. Targeting CTSB with p-CA provides a promising prophylactic or co-treatment candidate for HN warranting further translational evaluation.